Savas A, Erdem A, Tun K, Kanpolat Y
Department of Neurosurgery, Ankara University, School of Medicine, Turkey.
Neurosurgery. 2000 Jan;46(1):213-6; discussion 216-7.
Craniopharyngiomas are benign neoplasms of epithelial origin that arise from the remnants of Rathke's pouch and are located in the sellar, parasellar, and third ventricular regions. Despite major advances in microsurgical techniques, total removal of these tumors is associated with a high risk of death, long-term endocrinological dependence, cognitive dysfunction, and behavioral disorders. For patients with monocystic craniopharyngiomas, encouraging postoperative survival rates and high rates of cyst regression after intracavitary administration of bleomycin have been reported. Moreover, only a few side effects have been reported for this treatment method. We report a patient with a cystic craniopharyngioma who was treated using intracavitary bleomycin administration and died as a result of the direct toxic effects of bleomycin on deep brain structures and the brainstem.
A 47-year-old woman with a cystic craniopharyngioma underwent stereotactic insertion of a catheter attached to a subcutaneous reservoir. Five months after the procedure, positive-contrast computed tomographic cystography was performed to confirm the absence of fluid leakage. Daily intracavitary injections of bleomycin were administered through the reservoir into the cyst, until a total dose of 56 mg had been administered in 8 days. After the treatment, the cystic cavity regressed but the patient exhibited neurological deterioration; magnetic resonance imaging scans revealed diffuse edema in the diencephalon and brainstem. The patient died 45 days after completion of the treatment.
Intracavitary administration of bleomycin is not a treatment protocol without risks or side effects, even if there is no fluid leakage into the cerebrospinal fluid. Although this is known to be an effective treatment for cystic craniopharyngiomas, previous reports cannot be used to establish a standard treatment method, and more research is needed to yield a safer effective protocol.
颅咽管瘤是起源于上皮组织的良性肿瘤,由拉克囊残余组织发生,位于鞍区、鞍旁及第三脑室区域。尽管显微外科技术取得了重大进展,但完全切除这些肿瘤仍伴随着高死亡风险、长期内分泌依赖、认知功能障碍和行为障碍。对于单囊性颅咽管瘤患者,有报道称腔内注射博来霉素后术后生存率令人鼓舞,囊肿消退率也很高。此外,这种治疗方法仅报告了少数副作用。我们报告了一名囊性颅咽管瘤患者,接受腔内博来霉素注射治疗后,因博来霉素对深部脑结构和脑干的直接毒性作用而死亡。
一名患有囊性颅咽管瘤的47岁女性接受了立体定向插入连接皮下储液器的导管。术后五个月进行了阳性对比计算机断层扫描囊肿造影,以确认无液体渗漏。通过储液器每天向囊肿腔内注射博来霉素,直至在8天内共注射了56毫克的总剂量。治疗后,囊肿腔消退,但患者出现神经功能恶化;磁共振成像扫描显示间脑和脑干弥漫性水肿。患者在治疗完成后45天死亡。
即使没有脑脊液渗漏,腔内注射博来霉素也并非没有风险或副作用的治疗方案。尽管已知这是治疗囊性颅咽管瘤的有效方法,但以前的报告不能用于确立标准治疗方法,需要更多研究以产生更安全有效的方案。